#Liposomes Drug Delivery 2020 | Explore Tumblr posts and blogs

jayanthitbrc · 21 days ago

Text

Global Liposomal Doxorubicin Market Analysis 2024: Size Forecast and Growth Prospects

The liposomal doxorubicin global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Liposomal Doxorubicin Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The liposomal doxorubicin market size has grown strongly in recent years. It will grow from $1.15 billion in 2023 to $1.23 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to improved liposome formulations, favorable reimbursement policies for cancer treatments, growing awareness about the importance of cancer screening programs, enhanced healthcare infrastructure, and increasing patient preference for minimally invasive cancer treatments.

The liposomal doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising awareness about cancer treatment options, increasing clinical trials, increasing adoption of combination therapies, rising healthcare expenditure, and growing preference for targeted therapies. Major trends in the forecast period include the integration of artificial intelligence (AI) and machine learning algorithms to facilitate drug discovery, utilizing 3D printing technologies, magnetic targeting methods, innovative strategies such as tumor-penetrating peptides or ultrasound-mediated drug delivery, and advancements in drug delivery technology.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/liposomal-doxorubicin-global-market-report

Scope Of Liposomal Doxorubicin Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Liposomal Doxorubicin Market Overview

Market Drivers - The rising prevalence of cancer is expected to propel the growth of the liposomal doxorubicin market going forward. Cancer refers to a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their normal boundaries, and either spread to other organs or invade neighboring body parts. Cancer cases are rising due to factors such as an aging population, lifestyle changes, environmental exposures, and improved diagnostic techniques. Liposomal doxorubicin is used in cancer treatment to enhance drug delivery to tumors, reduce toxicity, and improve therapeutic outcomes. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase compared to more than 1.8 million new cancer cases diagnosed in 2020. Therefore, the rising prevalence of cancer is driving the growth of the liposomal doxorubicin market.

Market Trends - Major companies operating in the liposomal doxorubicin market are focusing on developing enhanced drug delivery systems, such as PEGylated liposomes to improve the pharmacokinetics and biodistribution of doxorubicin, leading to better patient outcomes. These innovations enhance the efficiency and precision of drug delivery, ensuring that medications are more effectively targeted to cancer cells while minimizing side effects. For instance, in May 2022, Accord Healthcare Limited, a US-based pharmaceutical company, launched Zolsketil, a pegylated liposomal 2mg/ml concentrate for dispersion for infusion. This product is a generic version of the cancer medication doxorubicin, which is commonly used to treat various types of cancer.

The liposomal doxorubicin market covered in this report is segmented –

1) By Product: Doxil Or Caelyx, Lipodox, Myocet, Other Products 2) By Route Of Administration: Parenteral, Other Routes Of Administration 3) By Application: Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, Other Applications 4) By End-Users: Hospitals, Homecare, Other End-Users

Get an inside scoop of the liposomal doxorubicin market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16464&type=smp

Regional Insights - North America was the largest region in the liposomal doxorubicin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - Major companies operating in the liposomal doxorubicin market are <b>Pfizer Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd, Baxter International Inc., Astellas Pharma, Sun Pharmaceutical Industries Ltd, Jazz Pharmaceuticals, Cipla Inc., Endo Pharmaceuticals, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila, Accord Healthcare Limited, Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.Ltd, TTY Biopharm Company Limited, SRS Life Sciences</b>

Table of Contents 1. Executive Summary 2. Liposomal Doxorubicin Market Report Structure 3. Liposomal Doxorubicin Market Trends And Strategies 4. Liposomal Doxorubicin Market – Macro Economic Scenario 5. Liposomal Doxorubicin Market Size And Growth ….. 27. Liposomal Doxorubicin Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected]

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

univdatosmarket · 6 months ago

Text

#Nanotechnology in Drug Delivery Marke

0 notes

emaanderson · 2 years ago

Text

Liposome Drug Delivery Market Size, Growth, Supply and Manufacturers Analysis Research Report 2031

Research Nester has released a report titled “Liposome Drug Delivery Market: Global Demand Analysis & Opportunity Outlook 2031” which also includes some of the prominent market analyzing parameters such as industry growth drivers, restraints, supply and demand risk, along with the impact of COVID-19 and a detailed discussion on the latest trends and future opportunities that are associated with the growth of the market.

In the year 2020, about 10 Million deaths across the globe were registered as a result of cancer disease, according to the statistics by the World Health Organization (WHO). Moreover, the statistics also stated that the disease is one of the leading causes of death worldwide.

The statistics portray the growing concern for the prevalence of chronic diseases and the surge in deaths caused due to the disease. Owing to such a factor, there is a growing need amongst the healthcare researchers to develop advanced drug delivery systems that can help to diagnose and treat the disease. Besides this, the surge in use of liposomes as drug delivery systems, backed by the numerous benefits associated with the use of the biochemical compound, is also expected to contribute to the market growth.

The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, i.e., 2022 – 2031. The market is estimated to garner a revenue of USD 11977.1 Million by the end of 2031. Additionally, in the year 2021, the market generated a revenue of USD 4356.7 Million. The market is segmented by product into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others, out of which, the liposomal doxorubicin segment is projected to garner the largest revenue of USD 3218.1 Million by the end of 2031. Moreover, the segment generated a revenue of USD 1142.1 Million in the year 2021.

By region, the global liposome drug delivery market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, the market in North America is projected to garner the largest revenue of USD 4429.6 Million by the end of 2031. Moreover, the market in the region generated a revenue of USD 1689.9 Million in the year 2021.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

However, the high cost of development of the drug delivery system is predicted to hinder the growth of the market in the coming years.

This report also provides the existing competitive scenario of some of the key players of the global liposome drug delivery market, which includes company profiling of Spectrum Pharmaceuticals, Inc., Gilead Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc., Astellas Pharma Inc., Elan Pharmaceuticals (Perrigo Company plc), Merrimack Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., and others. Besides this, some of the prominent raw material manufacturers in the global liposome drug delivery market that are included in our report are NIPPON FINE CHEMICAL CO., LTD., Sonic Biochem Extractions Pvt. Ltd., Croda International Plc, Lipoid GmbH, Hashimoto Electronic Industry Co., LTD, and others.

The profiling enfolds key information of the companies which comprises of business overview, products and services, key financials and recent news and developments. Conclusively, the report titled “Liposome Drug Delivery Market: Global Demand Analysis & Opportunity Outlook 2031”, analyses the overall global liposome drug delivery industry to help new entrants to understand the details of the market. In addition to that, this report also guides existing players looking for expansion and major investors looking for investment in the global liposome drug delivery market in the near future.

About Us

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

0 notes

awesomechrisharry · 4 years ago

Text

Liposomes Drug Delivery Market Size, Analysis, Demand and Forecasts By 2025

The Liposomes Drug Delivery Market report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Liposomes Drug Delivery marketing research is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. The report provides key information on the market status of the Liposomes Drug Delivery manufacturers and may be a valuable source of guidance and direction for companies and individuals curious about the industry.

The report provides detailed assessment of key market dynamics and extensive information about the structure of the Liposomes Drug Delivery industry. This market study contains exclusive insights into how the Liposomes Drug Delivery market is predicted to grow during the forecast period.

Request a sample Report of Liposomes Drug Delivery Market at: http://www.empiricaldatainsights.com/sample-request/10257

The report provides an in depth breakdown of the market region-wise and categorizes it at various levels. Regional segment analysis exhibit regional production volume, consumption volume, revenue, and rate of growth from 2020-2025

Leading Key Vendors:

Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, Sigma-Tau Group, Ipsen (Onivyde), CSPC, Teva Pharmaceutical, Novartis, Fudan-Zhangjiang

For Incredible Discount Ask @ http://www.empiricaldatainsights.com/discount-request/10257

According to Report By Product Types:

Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others

By Applications of the Liposomes Drug Delivery Market:

Fungal Infection Therapy, Cancer & Tumor Therapy, Others

Liposomes Drug Delivery Report By 2025

By Geographical Regions:

North America (the U.S., Canada)

Latin America (Brazil, Mexico, Argentina and other countries)

Asia Pacific (India, Japan, China, Australia and New Zealand and other countries)

Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries)

Middle East and Africa (GCC, South Africa, Israel and Other countries)

Reason to get Report:

The assessment of key growth dynamics highlights the attractiveness of latest technologies and offers readers insight on the prospect of those during the forecast period.

Provides an account of major breakthroughs altogether segments which may change the course of the market considerably.

The Liposomes Drug Delivery Market supported various factors- price analysis, supply chain analysis, Porte five force analysis etc.

Important trends, including proprietary technologies, ecological conservation, and globalization affecting the worldwide Liposomes Drug Delivery Market.

The report offers detailed analysis of main market trends with the impact of coronavirus.

Get Customization Ask Here @ http://www.empiricaldatainsights.com/customize-request/10257

About Us:

An optimally formulated blueprint is the main essence of a successful business. To prepare a similar blueprint - accurate and well-informed data is required to make simplified decisions. We at Empirical Data Insights assimilate the same quality of data through our discreetly prepared market reports. Providing the right data to businesses and cater to the process of decision making or capturing markets, is what we aim to do. Our reports will prove to be useful in each & every step of the chain and business process.

http://www.empiricaldatainsights.com/

([email protected])

#Liposomes Drug Delivery #Liposomes Drug Delivery demand #Liposomes Drug Delivery 2020

0 notes

mullanna91 · 4 years ago

Link

Various ways of consuming Drugs, injecting it via the skin one of the best ways for administrating any medicine. Aso has several methods like Other methods include gels, liposomes, cyclodextrins, and others.

#drug delivery #micronisation #micronization

1 note · View note

marketresearchlatestreports · 2 years ago

Text

Advanced Drug Delivery Market Future Outlook: Analyst View

The advanced drug delivery market is expected to expand at a CAGR of 16.0%, reaching the estimated value of USD 1,95,132.45mn between 2020 to 2030.

Researchmoz elucidates the market dynamics of the advanced drug delivery market including market size, growth drivers, restraints, trends, opportunities, segment dominance, and competitive edge.

The burgeoning chronic diseases are expected to strengthen the market during the forecast period.

Factors Driving and Restraining the Market

Some of the determinants of the growth of the advanced drug delivery market include-

The advanced technology in the drug delivery system is expected to drive the market towards significant growth.

For instance- West Pharmaceuticals getting into an agreement with Corning Incorporated for advanced technology for an advanced injectable drug delivery system to offer better safety for patients

Benefits such as target-oriented therapy, reduced dosing frequency, lower toxicity, and increased efficacy are anticipated to bolster the market significantly during the forecast period.

Rising investment in research and development in biotechnology and genetic engineering is expected to boost the demand for advanced drug delivery in the forthcoming years.

The controlled dosing system provides better patient compliance, and easy treatment methods, owing to the market expansion of advanced drug delivery during the forecast period.

The rapid development in nanotechnology and the development of nanoparticles to overcome the barriers of conventional methods of drug delivery are expected to drive the expansion of the market in the following years.

Analyst’s View

The global advanced drug delivery market is expected to grow exponentially at a noteworthy CAGR of 16.0% between 2020 to 20230, marking up to the estimated value of USD 1,95,132.45mn.

The first drug delivery system originated in 1855, in the form of syringes, however, it is since 1970 that the advent of the drug delivery system started gaining traction, now paving way for advanced drug delivery systems with next-generation drug delivery technologies.

The development of nanoparticles aims at the controlled release of drugs offering therapeutic efficacy and lower toxicity to meet the unmet needs in healthcare facilities.

Some of the existing key players of the advanced drug delivery market are –

Alnylam Pharmaceuticals Inc.

Endo International Plc.

Biogen Limited

Micropoint Technologies

Bausch Health Companies Inc. (Bausch & Lomb)

Altaris Capital Partners Llc. (Kindeva Drug Delivery)

Novo Nordisk A/S

Takeda Pharmaceutical Company Limited.

Johnson & Johnson (Johnson & Johnson Vision)

Ocular Therapeutix Inc.

https://www.beetribune.com/advanced-drug-delivery-market-key-insights/

Product/Type Disposition (Revenue in USD million)

Oral Drug Delivery System

Injection based Drug Delivery System

Inhalation/ Pulmonary Drug Delivery System

Transdermal Drug Delivery System

Parenteral Drug Delivery System

Application Disposition (Revenue in USD million)

Liposomes

Nano Particles

Microspheres

Monoclonal Antibodies

Others

End Users Dispositions (Revenue in USD million)

Hospitals

Specialized Clinics

Clinical Research & Development Centres

Regional Disposition

U.S.

Canada

UK.

Germany

France

China

India

Japan

South Korea

Brazil

Mexico

Key Takeaways

The development of smart drug delivery is quintessential for intelligently targeted therapeutics.

Groundbreaking approaches and strategies such as nanotechnology is expected to advance the treatment approaches and drug performances.

The controlled oral delivery system is expected to gain traction in the advanced drug delivery market due to being less expensive, easy to administer, and less painful as compared to other modes of drug delivery.

The market is moderately competitive; however, it is quite challenging to penetrate the market unless there is intensive research not just about the drugs but also about the possibilities of drug recalls and failures and their impacts.

Download Report PDF:

Advanced Drug Delivery Market

#Advanced Drug Delivery Market

0 notes

market-researcher · 2 years ago

Text

Liposome Drug Delivery Market To Grow on Account of Growing Prevalence of Cancer

For More Information About This Report Visit: https://www.researchnester.com/sample-request-4073

However, the high cost of development of the drug delivery system is predicted to hinder the growth of the market in the coming years.

Download a Sample Report with Table of Contents and Figures: https://www.researchnester.com/sample-request-4073

About Us

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

#Liposome Drug Delivery Market

0 notes

gurudige9987 · 3 years ago

Text

The global Liposomes Drug Delivery market size is projected to reach US$ 5921.5 million by 2030, from US$ 3087.7 million in 2020, at a CAGR of 10.0% during 2021-2030.

#Liposomes Drug Delivery market size

0 notes

1188ps · 3 years ago

Text

Nanotechnology Drug Delivery Market Investment Opportunities, Future Trends, Business Demand and Growth And Forecast 2027

Nanotechnology Drug Delivery Market Overview:

Maximize Market Research provides a brief description of the Nanotechnology Drug Delivery Market provides the latest snapshots of the market, and best understands its features. The report thoroughly covers analyzed insights in view of the market along with its ever-changing patterns, industry environment, and all dominant aspects of the market. This research methodology has been applied to examine the global Nanotechnology Drug Delivery market and these findings have been logically mentioned in this report.

Request for free sample: https://www.maximizemarketresearch.com/request-sample/39035

Nanotechnology Drug Delivery Market Scope:

Nanotechnology Drug Delivery Market Report provides in-depth knowledge and comprehension of trends, dynamics, and other topics. The research identifies the most important trends that will have an impact on the business. It aids in the identification of the information included in the research determining the competitive landscape of key companies, factors affecting the market, and other aspects that can help you determine whether your present marketing plans are on track and how to enhance them.

The qualitative and quantitative data provided in the Nanotechnology Drug Delivery Market study can help decision-makers understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunities areas.

Get more Report Details: https://www.maximizemarketresearch.com/market-report/global-nanotechnology-drug-delivery-market/39035/

Key Players:

• Johnson & Johnson • Merck & Co • Roche • Bayer • Novartis Pharmaceuticals • Pfizer • AstraZeneca • Amgen • Celgene Corporation • Angiotech Pharmaceuticals • Capsulution Pharma • AlphaRx Inc. • Calando Pharmaceuticals • Copernicus Therapeutics • Elan Corporation • Nanotherapeutics • PAR Pharmaceutica • Taiwan Liposome Co. • AbbVie, Inc • Amgen, Inc • Camarus AB • NanoCarrier Co., Ltd. • Selecta Biosciences • Starpharma Holdings Limited

The competitive environment is an important aspect that all major players need to be familiar with. The report highlights the competitive scenario of the global Nanotechnology Drug Delivery market to know the competition at both domestic and global levels. The most important aspects of applications, production, product portfolio, etc. In addition, the companies included in the report are considered based on key factors such as company size, market share, market growth, revenue, production, and profits. With

Player additional Nanotechnology Drug Delivery market share analysis, detailed profiling, product/services, and business overview, this study also focuses on BCG matrix, heatmap analysis, competitive benchmarking, and SWOT analysis.

Regional Analysis:

Geographically, this report is segmented into several key countries with market size, growth rate, import and export of Nanotechnology Drug Delivery market in these countries, which covers North America, U.S., Canada, Mexico, Europe, UK, Germany, France, Spain, Italy, Rest of Europe, Asia Pacific, China, India, Japan, Australia, South Korea, ASEAN Countries, Rest of APAC, South America, Brazil, and the Middle East and Africa.

As the largest market for acoustic materials, the Asia Pacific region has witnessed a Significant Increase. The Asia-Pacific region manufactured the most automobiles globally in 2020. The region is expected to be the largest market for Nanotechnology Drug Delivery materials in terms of both volume and value. The vast car manufacturing in the region represents a significant potential opportunity for the acoustic materials sector.

Europe is the world's second-largest market for passenger cars, particularly high-end models. During the projection period, premium automotive sales are predicted to expand linearly, boosting demand for acoustic materials in Europe.

COVID-19 Impact Analysis on Nanotechnology Drug Delivery Market:

The report identified the detailed impact of COVID 19 on the Nanotechnology Drug Delivery market in regions such as North America, Asia Pacific, the Middle East, Europe, and South America. The report provides a comprehensive analysis of Nanotechnology Drug Delivery market alternatives, harsh conditions, and harsh scenarios during this crisis. The report briefly describes the profits and financial and market growth difficulties encountered during COVID 19. In addition, the report provides some concepts to help readers determine and plan their business strategy.

Key Questions Answered in the Nanotechnology Drug Delivery Market Report are:

Which product segment grabbed the largest share in the Nanotechnology Drug Delivery market?

What is the competitive scenario of the Nanotechnology Drug Delivery market?

Which are the key factors aiding the Nanotechnology Drug Delivery market growth?

Which region holds the maximum share in the Nanotechnology Drug Delivery market?

What will be the CAGR of the Nanotechnology Drug Delivery market during the forecast period?

Which application segment emerged as the leading segment in the Nanotechnology Drug Delivery market?

Which are the prominent players in the Nanotechnology Drug Delivery market?

What key trends are likely to emerge in the Nanotechnology Drug Delivery market in the coming years?

What will be the Nanotechnology Drug Delivery market size by 2027?

Which company held the largest share in the Nanotechnology Drug Delivery market?

About Us:

Maximize Market Research provides B2B and B2C research on 12000 high growth ever balanced Salt Solutions opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

MAXIMIZE MARKET RESEARCH PVT. LTD.

3rd Floor, Navale IT Park Phase 2,

Pune Bangalore Highway,

Narhe, Pune, Maharashtra 411041, India.

Email: [email protected]

Phone No: +91 20 6630 3320

Website: www.maximizemarketresearch.com

Related Link: https://www.marketwatch.com/press-release/rapid-medical-diagnostic-kits-market-investment-opportunities-future-trends-business-demand-and-growth-forecast-2027-2022-02-18?mod=search_headline

https://www.marketwatch.com/press-release/global-clinical-trial-supplies-market-share-size-movements-by-key-finding-impact-latest-trends-analysis-progression-status-revenue-and-forecast-to-2027-2022-02-18?mod=search_headline

https://www.marketwatch.com/press-release/gene-editing-market-development-key-opportunities-and-analysis-of-key-players-to-2027-2022-02-18?mod=search_headline

0 notes

marketinsightshare · 3 years ago

Text

Drug Delivery Across Blood Brain Barrier Market Size Estimated to Reach $ 4,627.3 Million by 2026

Drug Delivery across Blood Brain Barrier Market size is estimated to reach $ 4,627.3 million by 2026, growing at a CAGR of 5% over 2021-2026. The blood brain barrier helps to protect the brain from harmful chemicals and maintains a constant environment. The blood brain barrier is a kind of protecting structure that provides a control on passage that moving from blood to the tissues of the central nervous system. Liposomes are an important tool to transfer drugs across the blood brain carrier owing to their flexible properties. The blood brain barrier are formed by the brain microvascular endothelial cells, a central element of the microvasculature that guard the brain against toxins. Growing incidence of neurological disorders and rising technological advancements is the major factor driving the growth of this market. Furthermore, rising prevalence of dementia and development in magnetic resonance imaging helps to detect blood brain barrier that can predict stroke patient’s is set to further enhance the overall market demand for Drug Delivery across Blood Brain Barrier Market for the period 2021-2026.

Drug Delivery Across Blood Brain Barrier Market Segment Analysis - By Technology

The global Drug Delivery across Blood Brain Barrier Market based on Technology can be further segmented into Trojan Horse Approach, Bispecific Antibody RMT Approach, Increasing Permeability, Passive Diffusion, Others. The Increasing Permeability of blood brain barrier segment is the major segment generating revenue in 2020. This is owing to rising number of research activities for the treatment of various neurological and CNS (Central Nervous System) Disorders. The Trojan Horse Approach segment is estimated to register the fastest CAGR of 3.8% for the period 2021-2026. This is owing to increasing demand of biologics for treating brain disorders. Biologics are also considered as a new therapy for treating most CNS (Central Nervous System) disorders.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=19550

Report Price: $ 4500 (Single User License)

Drug Delivery Across Blood Brain Barrier Market Segment Analysis - By Application

The global Drug Delivery across Blood Brain Barrier Market based on Application can be further segmented into Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, Multiple Sclerosis, Hunter’s Syndrome, Brain Cancer, Others. The Parkinson’s Disease segment registers for the highest market share in 2020. According to National institute on Aging, in 2020 about 5-10% of people have parkinson’s at the age of 50 and are mostly occur in men. The Epilepsy segment is estimated to register the fastest CAGR of 1.2% over 2021-2026. According to World Health Organization in 2019, about 50 million people are affected by epilepsy which increases the growth of this segment.

Drug Delivery Across Blood Brain Barrier Market Segment Analysis - By Geography

North America dominated the Drug Delivery across Blood Brain Barrier Market with major share of 45% in 2020. This is owing to increasing adoption of advanced technology for treating severe life-threatening disorders, rising prevalence of Hunter’s and Azheimer’s syndrome. According to National Institute of Health, about 5.5 million Americans are suffering from Alzheimer’s in 2020 which are contributing to the rise in market growth.

However, Asia-Pacific is estimated to outpace all the regions by clocking the highest CAGR of 20% during the forecast period 2021-2026 owing to the increasing geriatric population and improving innovative technologies.

Drug Delivery across Blood Brain Barrier Market Drivers

Growing Incidence of Neurological Disorders

The increasing prevalence of neurological diseases such as meningitis, multiple sclerosis, Parkinson’s disease, and encephalitis, growing geriatric population increases the growth of the Drug Delivery across Blood Brain Barrier Market. Moreover, rising demand for treatment and rise in the innovations helps safe and reliable transmission of medication. Thus, increasing the growth of the Drug Delivery across Blood Brain Barrier Market over 2021-2026.

Rising Technological Advancement

Growing technological advancement and rising healthcare sector is increasing the growth of the Drug Delivery across Blood Brain Barrier Market. Moreover, increasing use of nanotechnology in treating various medical conditions and rising development in magnetic resonance imaging increases the growth of Drug Delivery across Blood Brain Barrier Market over 2021-2026.

Covid-19 Impact:

COVID-19 is adversely impact the growth of Drug Delivery across Blood Brain Barrier Market. Moreover, recent clinical studies believed that people suffering from Central Nervous System complications are more susceptible to COVID-19 infection owing to low immunity that positively affected the growth of Drug Delivery across Blood Brain Barrier Market.

Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=19550

Drug Delivery across Blood Brain Barrier Market Challenges

Leakage in Blood Brain Barrier

The factors that is set to impede the growth of the Drug Delivery across Blood Brain Barrier Market are the rising risk in leakage of blood brain barrier that can enter harmful substances. Moreover, it takes out all the nutrients is set to create hurdles for the Drug Delivery across Blood Brain Barrier Market.

Drug Delivery across Blood Brain Barrier Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Drug Delivery across Blood Brain Barrier Market. Key companies of this market include Ossianix, Inc., Amneal Pharmaceuticals Inc., Insightec, Angiochem Inc., Armagen Technologies, Inc., BrainsGate, BiOasis Technologies, Inc., CarThera, F. Hoffman La-Roche, and Iproteos S.L.

Key Takeaways

Geographically, in 2020 North America dominated the Drug Delivery across Blood Brain Barrier Market owing to increasing adoption of advanced technology for treating severe life-threatening disorders, rising prevalence of hunter’s and alzheimer’s syndrome.

Growing incidence of neurological disorders and rising technological advancements are likely to aid in the market growth of the Drug Delivery across Blood Brain Barrier.

Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Drug Delivery across Blood Brain Barrier Market report.

Leakage in blood brain barrier is set to create hurdles for the Drug Delivery across Blood Brain Barrier Market.

Related Reports :

A. Nanotechnology Drug Delivery Market

https://www.industryarc.com/Report/16071/nanotechnology-drug-delivery-market.html

B. Drug Delivery Market

https://www.industryarc.com/Report/10599/drug-delivery-market-analysis.html

For more Chemicals and Materials Market reports, Please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

#Drug Delivery Across Blood Brain Barrier Market share Drug Delivery Across Blood Brain Barrier Market size Drug Delivery Across Blood Brain

0 notes

healthcare-market · 3 years ago

Text

Ocular Drug Delivery System Market Analysis and Outlook Report

Ocular Drug Delivery System Market: Overview

The ocular drug delivery system market is predicted to chart a notable growth trajectory over the forecast period from 2020 to 2030. Firstly, surge in the number of eye procedures that require attentive post procedural care displays demand for ocular drug delivery system. Ocular drug delivery system is designed to treat the eye locally, contrary to conventional drug delivery methods are less effective due to the presence of several barriers.

The report studies the ocular drug delivery system market on the basis of technology, end user, indication type, and geography

Read Report Overview: https://www.transparencymarketresearch.com/ocular-drug-delivery-system-market.html.

The report studies the ocular drug delivery system market from ground-up to provide an exhaustive analysis of growth trends and opportunities in the said market for the 2020 – 2030 forecast period. In addition, the report analyzes key segments of the ocular drug delivery system market, including growth rate projections of key segments for the 2020 – 2030 forecast period. Lastly, the report examines the vendor landscape of the ocular drug delivery system market at length. This section covers growth strategies of large players in the ocular drug delivery system market along with their revenue share projections for the above mentioned forecast period.

Request a Sample of Ocular Drug Delivery System Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=81294

Ocular Drug Delivery System Market: Competitive Landscape

The ocular drug delivery system market marks the presence of some well-entrenched players that hold sizeable share. Keen players in the ocular drug delivery system market are engaging in collaborations and partnerships, particularly with small players to be deemed to have a consolidated vendor landscape. Besides this, immense R&D for novel products is another key growth strategy of keen players in the ocular drug delivery system market.

Prominent players in the ocular drug delivery system market include Ocular Therapeutix Inc., Allergan plc., Graybug Vision Inc., Santen Pharmaceutical Co. Ltd., Envisia Therapeutics, Alimera Sciences, pSivida, Taiwan Liposome Company Ltd., and Clearside Biomedical among others.

Enquiry before Buying Ocular Drug Delivery System Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=81294

Ocular Drug Delivery System Market: Key Trends

Availability of a slew of technologies within ocular drug delivery system expands its use, thereby benefitting the ocular drug delivery system market. Intravitreal injection, nanoparticles iontophoresis, and ocular inserts are some technologies within the ocular drug delivery system approach.

The various advantages of ocular drug delivery system for pharmacologists and formulation scientists for drug delivery into targeted ocular tissues is a plus for the growth of ocular drug delivery system market. For example, ocular drug delivery system helps to cross barriers and their associated side effects, and help maintain drug concentration for extended period of time which gives better results in terms of patient comfort, safety, and effectiveness.

Request For Discount - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=81294

Immense R&D in nanotechnology has helped drug delivery scientists to moderate the process and use it to develop error-free drug delivery techniques, including ocular drug delivery system. The vast unmet demand for ocular drug delivery system is impelling manufacturers to create avant-garde products. Further advancements in predecessor ocular drug delivery system resulting in in situ gels and contact lens continues to create opportunities in the ocular drug delivery system market. Product manufacturers are also making efforts to fabricate ocular implants and ocular inserts, with funding assistance from a number of venture capital firms that have business interest in such pursuits.

Pre-book Ocular Drug Delivery System Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=81294&ltype=S

Ocular Drug Delivery System Market: Regional Assessment

North America dominates the ocular drug delivery system among other key regions in the ocular drug delivery system. Factors such as increasing incidence of ophthalmic disorders, initiatives undertaken by government agencies, and rising incidence of macular degeneration and glaucoma are fuelling the ocular drug delivery system market in the region.

Asia Pacific is emerging as a key region in the ocular drug delivery system market. Advancement in medical care and awareness among patients is leading to surge in demand for targeted drug delivery techniques such as ocular drug delivery.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/increasing-adoption-of-targeted-cancer-therapies-to-propel-oncolytic-virus-immunotherapy-market-says-tmr-301347104.html

https://www.prnewswire.com/news-releases/initiatives-undertaken-by-various-countries-to-legalize-use-of-cannabis-for-medical-purposes-to-ensure-growth-of-medical-cannabis-market-says-tmr-301353174.html

https://www.prnewswire.co.uk/news-releases/growing-popularity-of-portable-mobile-systems-among-veterinary-practitioners-animal-stable-owners-to-expand-growth-potential-of-veterinary-radiography-system-market-notes-tmr-831702983.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact:

Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com

0 notes

your-dietician · 3 years ago

Text

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

New Post has been published on https://depression-md.com/tlc-reports-second-quarter-2021-financial-results-and-provides-business-update/

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) — TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

“The second quarter of 2021 was marked mainly by the timely approval of our liposomal amphotericin B product in India and the immediate partnerships for their commercialization and sales in the territory,” commented George Yeh, President of TLC. “We are grateful to have the ability to be of assistance in this humanitarian crisis brought about by the COVID-19 pandemic by fulfilling an unmet need, and will continue our quest to provide best-in-class treatments in pain management, ophthalmology, oncology, as well as infectious diseases.”

Clinical Pipeline Update and Upcoming Milestones

All subjects have reached the 24-week timepoint in EXCELLENCE. The Phase III pivotal clinical trial of TLC599 in ~500 subjects is progressing smoothly, with all subject having reached the 24-week timepoint and the majority of whom having received the second injection of either TLC599 or placebo. There remains no safety concerns or serious adverse events related to treatment. The multi-center, randomized, double-blind, active comparator- and placebo-controlled pivotal study is evaluating the efficacy and safety of a single and a repeat dose of TLC599 in patients with knee osteoarthritis across 46 sites in the United States and Australia.

Pivotal clinical trial of TLC590 to kick off soon. Following a fruitful End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA), TLC has accrued additional guidelines on the design parameters for the pivotal clinical trials of TLC590 for post-operative pain and will be kicking off the next trial soon.

Liposomal amphotericin B receives approval in India. The Central Drugs Standard Control Organization (CDSCO) of India approved the New Drug Application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad® in Taiwan and AmphoTLC™ in India). The registration allows for immediate importation per approved usage and indication to aid in the country’s acute shortage of treatments for COVID-19 associated mucormycosis.

Presented data on advantages of inhalable liposome formulations of antiviral drugs for lung diseases at ISAM. At the 23rd International Society for Aerosols in Medicine (ISAM) Congress, TLC’s subsidiary, InspirMed, presented data from pharmacokinetic studies on ISPM21 (inhalable liposomal GS-441524, main plasma metabolite of remdesivir), and ISPM19 (inhalable liposomal hydroxychloroquine) that showed significantly higher concentrations in the lungs than their conventional counterparts, suggesting feasibility of higher dosing without hepatotoxicity or nephrotoxicity as an improvement upon current treatments.

Corporate Highlights

Story continues

Commercialization of liposomal amphotericin B in India. Following the new drug registration, TLC entered non-exclusive partnerships with Zydus Healthcare Limited and Strides Pharma Science Limited to begin immediate distribution of its liposomal amphotericin B product in India.

Partnership with Endo International plc for the commercialization of a liposomal product. TLC is eligible to receive upfront and subsequent milestone payments as well as a double-digit share of the net profits from product sales in the United States.

Stock swap and restructuring. Details of the share swap transactions and restructuring with Woods Investment Company, along with a list of frequently asked questions, can be found on the company website (www.tlcbio.com) under Investors/Shareholder Resources/Share Swap.

Expanded global intellectual property protection to 314 patents, with 165 patents granted and 149 applications worldwide as of June 30, 2021.

Financial Results

Operating revenue for the second quarter of fiscal 2021 was NT$160.2 million (US$5.7 million), a 1,260.2% increase compared to NT$11.8 million (US$0.4 million) in the second quarter of fiscal 2020. Operating expenses for the second quarter of fiscal 2021 was NT$251.7 million (US$9.0 million), a 6.2% decrease compared to NT$268.4 million (US$9.1 million) in the second quarter of fiscal 2020. Net loss for the second quarter of fiscal 2021 was NT$75.5 million (US$2.7 million), compared to a loss of NT$242.4 million (US$8.2 million) in the second quarter of 2020, or a net loss of NT$0.66 (US$0.02) per share for the second quarter of fiscal 2021, compared to a net loss of NT$3.28 (US$0.11) per share for the second quarter of fiscal 2020.

The Company’s cash and cash equivalents were NT$696.7 million (US$25.0 million) as of June 30, 2021, compared to NT$1,342.7 million (US$47.8 million) as of December 31, 2020.

Financial Summary

Selected Consolidated Balance Sheet Data

December 31, 2020

June 30, 2021

NT$000

US$000

NT$000

US$000

Cash and cash equivalents and time deposit

1,342,667

47,816

696,737

24,964

Total current assets

1,431,977

50,997

986,874

35,359

Total assets

1,749,461

62,303

1,330,969

47,688

Total current liabilities

348,127

12,398

327,849

11,747

Long-term borrowings

469,076

16,705

372,809

13,357

Total liabilities

886,134

31,557

775,191

27,775

Total equity

863,327

30,746

555,778

19,913

Selected Consolidated Statements of Operations Data

Three-month periods ended June 30,

Six-month periods ended June 30,

2020

2021

2020

2021

NT$000

US$000

NT$000

US$000

NT$000

US$000

NT$000

US$000

Operating revenue

11,776

400

160,176

5,739

23,750

807

197,794

7,087

Operating expenses

General and administrative expenses

(39,487

)

(1,341

)

(31,622

)

(1,133

)

(72,367

)

(2,458

)

(62,669

)

(2,245

)

Research and development expenses

(228,881

)

(7,774

)

(220,087

)

(7,886

)

(420,659

)

(14,289

)

(442,861

)

(15,868

)

Total operating expenses

(268,368

)

(9,115

)

(251,709

)

(9,019

)

(493,026

)

(16,747

)

(505,530

)

(18,113

)

Loss before income tax

(242,089

)

(8,223

)

(75,144

)

(2,692

)

(456,253

)

(15,498

)

(293,142

)

(10,503

)

Income tax expense

(348

)

(12

)

(363

)

(13

)

(769

)

(26

)

(602

)

(22

)

Net loss

(242,437

)

(8,235

)

(75,507

)

(2,705

)

(457,022

)

(15,524

)

(293,744

)

(10,525

)

Total other comprehensive loss

1,698

(13,090

)

(469

)

(1,808

)

(61

)

(21,285

)

(762

)

Total comprehensive loss

(240,739

)

(8,177

)

(88,597

)

(3,174

)

(458,830

)

(15,585

)

(315,029

)

(11,287

)

Loss per share of common stock

Basic and diluted loss per share (in dollars)

(3.28

)

(0.11

)

(0.66

)

(0.02

)

(6.18

)

(0.21

)

(3.05

)

(0.11

)

About TLC

TLC is a clinical-stage, specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®), including BioSeizer® sustained release technology and NanoX® active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics targeting areas of unmet medical need in pain management, ophthalmology, oncology and infectious diseases.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, without limitation, statements regarding TLC’s expectations regarding the clinical development of TLC’s product and product candidates, including Ampholipad, TLC599, TLC590, ISPM21 and ISPM19, the clinical benefits of TLC’s products and product candidates, the timing, scope, progress and outcome of TLC’s clinical trials and regulatory communications, the timing, scope, progress and outcome of TLC’s collaborations and partnerships, the commercialization of TLC’s products, how sufficient cash and equivalents will be to fund operations, the anticipated timelines for the release of clinical data and progress of TLC’s manufacturing capabilities. Words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval, and delays or disruptions on our business or clinical trials due to the COVID-19 pandemic. Other risks are described in the Risk Factors section of TLC’s annual report on Form 20-F for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (the “SEC”) as well as subsequent filings with the SEC. All forward-looking statements are based on TLC’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

CONTACT: TLC Contact: Dawn Chi Corporate Communications [email protected]

Source link

0 notes

amitshinde7793 · 3 years ago

Text

Impact of COVID-19 on Amphotericin B in Healthcare Industry

COVID-19 Impact on Amphotericin B in Healthcare Industry

The outbreak of the coronavirus disease started in the city of Wuhan, China, in December 2019. Since then, it has spread horrendously throughout the world at a rapid speed, and many individuals have been affected by this viral disease. This pandemic is creating a problem for many drug manufacturing companies, including companies responsible for Amphotericin B production, as different countries have adopted different kinds of quarantine policies across the globe.

AMPHOTERICIN B and COVID-19

Amphotericin B is an anti-mycotic drug that is used to treat fungal infections. It is intravenously administered to treat potentially life-threatening fungal infections such as torulose, aspergillosis, systemic candidiasis, histoplasmosis, and mucormycosis.

Mucormycosis is a fungal disease that occurs when a person comes in contact with mucor. This disease affects the sinuses, lungs, and brain. It can be life-threatening in immune-compromised patients. People affected by mucormycosis are rising lately. Doctors believe that the steroids used to treat COVID-19 patients are triggering these cases of mucormycosis. Steroids help in reducing the inflammation of the lung of COVID patients, but on the others hand; it decreases the overall immunity of the body. This drop-in immunity can be triggering cases of mucormycosis.

PRICE IMPACT

India is considered as one of the global leaders when it comes to drug supply to other countries. It has already been forecasted that India’s API will reach revenue of USD 6.00 billion by the end of 2020. India exports 30 percent of the API’s used in the U.S, and also, the majority of API’s required by different companies across the world for the manufacture of generic drugs is supplied by India. But India imports almost 65 percent of its total bulk API requirements from China for the medicine formulations. During this pandemic period, as China’s competitiveness towards India is increasing, they are raising the cost of their API’s which would ultimately result in the disruption of the drug manufacturing market and would increase their prices.

As rising cases of Mucormycosis on COVID-19 patients are observed, the anti-fungal drug demand is also increased, which resulted in the price hike and black marketing of this life-saving amphotericin B drug.

For instance,

· Two persons have been caught in Chandigarh, Haryana, for black marketing amphotericin B drug. They were trying to sell one vial of amphotericin B for USD 164.83

IMPACT ON DEMAND

Mucormycosis has close ties with COVID-19 as people affected by coronavirus are also affected by mucormycosis if proper hygienic conditions are not maintained as the world sees a new rise in the number of coronavirus-infected cases. It is expected that people getting affected by mucormycosis will surge. The demand for amphotericin B is going to increase as it is an effective treatment for mucormycosis.

Due to the lockdown regulations, many drug manufacturing companies have been suffering to deal with the market demand. The government has taken initiatives to deal with the rising demand for the drug.

For instance,

· The cabinet approved an investment of USD 13.94 Billion to increase APT production, out of which USD 4.2 billion was for mega parks and USD 9.4 Billion was the support of Industry domestic production efforts

· Almost 27 API’s were planned to be made through chemical synthesis, and 26 API’s were to be made through fermentation. API’s for drugs like ganciclovir and valganciclovir are also supposed to be manufactured

· The government of India has licensed 5 manufacturers to produce amphotericin B production due to the rise of mucormycosis cases

This shows that the initiative taken by the government is helping to tackle this COVID-19 situation as amphotericin B needed for the treatment for mucormycosis are now starting to get manufactured domestically and the situation is likely to get better in the future.

IMPACT ON SUPPLY CHAIN

COVID-19 has led to a disruption in the supply chain of drugs. Lockdown policies in different countries have resulted in pharmacies closing walk-in customers to prevent the spread of the disease. This leaded to increased demand for home delivery and mail delivery systems. This led to a significant delay in the supply of the drugs. Also, during the lockdown period, the market for online delivery of drugs has seen a rise, which is normal considering the situation.

As many pharmaceutical companies are dependent on China for the supply of API’s their recent price hike has disrupted the manufacturing process of the drugs. Due to this, many companies are looking to diversify their API gathering according to their geographic location. The demand for lipids used for the manufacture of amphotericin B has seen a sharp rise due to rising mucormycosis cases, but the supply of those lipids is not ample as the drug was rarely used previously.

The investment made by the government of India for domestic manufacturing of amphotericin B will make the future of mucormycosis treatment in India a lot better.

A complete ban on the import of different goods from other countries has completely disrupted the supply chain.

The leading companies of the amphotericin B market worldwide have taken strategic steps to properly supply their drugs to people across the world.

For instance,

· Sun Pharmaceutical Industries Ltd., a leading manufacturer of amphotericin B has maintained its drug supply across the world. They formed a licensing agreement with Eli Lilly for the manufacturing and distribution of barcitinib in India, which is used alongside remdesivir to treat coronavirus infected patients

· Cipla Inc., a leading manufacturer, has maintained its supply chain during the pandemic. They have included remdesivir, favipiravir in their manufacturing portfolio. They have also formed an agreement for the distribution of Roche’s Actemra

This shows that even if the COVID-19 situation is disrupting the supply chain of API’s and the manufacture of drugs, the government of India and different major companies is creating a hope for the proper supply of drugs.

STRATEGIC DECISIONS FOR MANUFACTURERS

COVID-19 can hamper the production of amphotericin B, but it also allows companies to improve their business by different means. As a pharmaceutical company always does, they tend to find newer and better ways to treat a disease; same is the case for mucormycosis. Always bringing better solutions in the market would increase their business efficiency.

For instance,

· VAV Lifesciences, a leading manufacturer of the lipids required for the manufacturing of amphotericin B is planning to increase their manufacturing capacity of lipids from 21kgs of lipid per month to 130kgs of lipid per month

· TLC, a clinical-stage specialist pharmaceutical company announced that CDSCO of India had approved the new drug application AmphoTLC (amphotericin B) to meet the shortages of liposomal amphotericin B

This signifies that despite this COVID-19 situation, different strategic decisions made by these companies would make their business grow.

CONCLUSION

As this pandemic situation has resulted in many restrictions around different places globally, the market leaders of amphotericin B market have been able to manage their drugs stock. The supply chain was destroyed as most of the drug manufacturing companies did not get their API’s for the proper drug formulation, but the government of India took several steps and as well as different companies which will help them to get their needed API’s and properly carry out the drug manufacturing process. New companies have been approved for the manufacturing of amphotericin B, and also new drug applications are getting accepted to meet the shortages of amphotericin B as the number of cases of mucormycosis is rising. By increasing the raw materials price, the companies can maintain their overall revenue. Thus different companies of this amphotericin B market find their ways to deal with this pandemic situation.

#Amphotericin B Market #Amphotericin B Market Forcast #Amphotericin B Market Future Innovatio

0 notes

marketresearchlatestreports · 2 years ago

Text

Advanced Drug Delivery Market: Key Players to Gain Competitive Advantage

The advanced drug delivery market is expected to expand at a CAGR of 16.0%, reaching the estimated value of USD 1,95,132.45mn between 2020 to 2030.

Researchmoz elucidates the market dynamics of the advanced drug delivery market including market size, growth drivers, restraints, trends, opportunities, segment dominance, and competitive edge.

The burgeoning chronic diseases are expected to strengthen the market during the forecast period.

Factors Driving and Restraining the Market

Some of the determinants of the growth of the advanced drug delivery market include-

The advanced technology in the drug delivery system is expected to drive the market towards significant growth.

For instance- West Pharmaceuticals getting into an agreement with Corning Incorporated for advanced technology for an advanced injectable drug delivery system to offer better safety for patients

Benefits such as target-oriented therapy, reduced dosing frequency, lower toxicity, and increased efficacy are anticipated to bolster the market significantly during the forecast period.

Rising investment in research and development in biotechnology and genetic engineering is expected to boost the demand for advanced drug delivery in the forthcoming years.

The controlled dosing system provides better patient compliance, and easy treatment methods, owing to the market expansion of advanced drug delivery during the forecast period.

Analyst’s View

The global advanced drug delivery market is expected to grow exponentially at a noteworthy CAGR of 16.0% between 2020 to 20230, marking up to the estimated value of USD 1,95,132.45mn.

The development of nanoparticles aims at the controlled release of drugs offering therapeutic efficacy and lower toxicity to meet the unmet needs in healthcare facilities.

Some of the existing key players of the advanced drug delivery market are –

Alnylam Pharmaceuticals Inc.

Endo International Plc.

Biogen Limited

Micropoint Technologies

Bausch Health Companies Inc. (Bausch & Lomb)

Altaris Capital Partners Llc. (Kindeva Drug Delivery)

Novo Nordisk A/S

Takeda Pharmaceutical Company Limited.

Johnson & Johnson (Johnson & Johnson Vision)

Ocular Therapeutix Inc.

Read More: https://www.beetribune.com/advanced-drug-delivery-market-key-insights/

Product/Type Disposition (Revenue in USD million)

Oral Drug Delivery System

Injection based Drug Delivery System

Inhalation/ Pulmonary Drug Delivery System

Transdermal Drug Delivery System

Parenteral Drug Delivery System

Application Disposition (Revenue in USD million)

Liposomes

Nano Particles

Microspheres

Monoclonal Antibodies

Others

End Users Dispositions (Revenue in USD million)

Hospitals

Specialized Clinics

Clinical Research & Development Centres

Regional Disposition

North America

U.S.

Canada

Europe

UK.

Germany

France

Asia Pacific

China

India

Japan

South Korea

Latin America

Brazil

Mexico

Middle East & Africa (MEA)

Key Takeaways

The development of smart drug delivery is quintessential for intelligently targeted therapeutics.

Groundbreaking approaches and strategies such as nanotechnology is expected to advance the treatment approaches and drug performances.

Download Report PDF: Advanced Drug Delivery Market

#Advanced Drug Delivery Market

0 notes

marketresearchstrategy · 3 years ago

Text

Nanomedicine Market Size, Share, Growth, Sales Revenue and Key Drivers Analysis Research Report by 2027

Increasing incidence of cancer coupled with rising federal support in North America is expected to stimulate market growth.

The global nanomedicine market is expected to reach USD 435.08 billion by 2028, according to a new report by Reports and Data. Increased global incidence of cancer coupled with growing prevalence of cardiovascular diseases is likely to be the key factors governing market growth. Based on the WHO statistics, in 2018 around 18.07million new cases were registered for cancer in 2018. Additionally, cancer accounted for around 9.5 million deaths in 2018. The incidence of cancer was significantly high and lied around 48.4 percent in Asia Pacific.

Nanomedicine is being increasingly adopted for the treatment of various diseases including cancer and cardiovascular disease. Apart from improved efficacy and safety, factors such as bio-availability and ability to deliver diagnostic and therapeutic agents to targeted sites are expected to stimulate market growth.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1048

Some of the key players operating in the Nanomedicine market include:

Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation, and Johnson & Johnson.

Segments covered in the report:

On the basis of regional analysis, the market is segmented into key geographical regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. According to the analysis, North America is expected to dominate the market with the highest market share. Asia-Pacific is anticipated to show a significant growth rate owing to rising development and population demands.

Product Outlook (Revenue, USD Billion; 2017-2027)

Therapeutics

Regenerative Medicine

In-vitro diagnostics

In-vivo diagnostic

Vaccines

Drug Delivery System Outlook (Revenue, USD Billion; 2017-2027)

Nanobots

Nanoghosts

Nanoclusters

Nanobubbles

Exosomes

Injectable Nanoparticle Generator

Dendrimers

Liposomes

Carbon nanotube

Graphene

Others

Application Outlook (Revenue, USD Billion; 2017-2027)

Oncology

Infectious diseases

Cardiology

Orthopedics

Others

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048

Beneficial Aspects of the Report:

Global and region forecast of the Nanomedicine market from 2020-2027

In-depth analysis of market dynamics, industry outlook, market size based on types and applications

Details of value chain analysis, supply and demand ratio, production and consumption patterns

SWOT Analysis, Porter’s Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis to provide a better understanding of the market and competitive players

Detailed insights on competitive landscape and emerging market trends

Research Methodology:

The market report is formulated on the basis of data obtained through extensive primary and secondary research. The data is further validated and verified by industry experts, research analysts, and professionals. The report considers regional demand and supply ratio, investments, market dynamics, capacity, end-use industry trends, and consumer behavior to generate a forecast report. The data is collected from verified sources such as government policies, regulatory published materials, journals, trade magazines, and verified data sources. The report uses advanced analytical tools such as SWOT Analysis, Porter’s Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis to provide an accurate insight into the market scenario and competitive landscape. This report provides beneficial information to companies and new players to make lucrative business decisions. The market estimates and forecast data have been thoroughly verified through exhaustive primary research.

To read more about the report – https://www.reportsanddata.com/report-detail/nanomedicine-market

Thank you for reading our report. Reports and Data provides customization of the report as per the needs of the clients. For further inquiry on customization, please connect with us and our team will ensure the report is tailored to fit your requirements.

Browse More Reports:-

Hernia Mesh Market Share

Spun Bond Non-Woven Market Size

0 notes

marketresearchtrendsblog · 3 years ago

Text

Global Nanotechnology in Drug Delivery Market: Current Analysis and Forecast (2020-2027)

Nanotechnology provides superior drug delivery systems for better control and treatment of diseases by manipulating the properties of materials such as polymers and creating nanostructures. There are various advantages to the nanostructures employed as drug delivery systems that make them advanced to conventional delivery systems. Nanoparticles have emerged as key players in modern medicine in recent years, with applications ranging from contrast agents in medical imaging to gene delivery carriers in individual cells. Researchers are working on the utilization of nanoparticles to make drugs even more effective by having an in-depth understanding of the interaction of nanoparticles with cells, and the optimal toxicity or concentration. In this sector, healthcare R&D is seeing increased expenditure on nanosized materials and devices. A developing number of nanotherapeutic drugs have been commercialized or reached the clinical stage in recent years. Compared to traditional drugs, enhanced pharmacokinetics, biocompatibility, tumor targeting, and stability are associated with NP-based drug delivery systems, while simultaneously playing an important role in minimizing systemic toxicity and overcoming drug resistance. For oncology applications, over 20% of the therapeutic nanoparticles already in clinics or under clinical evaluation have been created. Most FDA-approved therapeutic nanoparticles are currently being designed for the re-formulation of combinations of chemotherapeutic drugs with polymeric nanoparticles. According to the WHO, CVDs kill 17.9 million people per year, an estimated 31% of all deaths worldwide. For the treatment of cardiovascular diseases, the use of nanoparticle-based formulations is primarily focused on targeted delivery and increasing bioavailability for vascular restenosis. Up to 23.5 million Americans (more than 7% of the population) suffer from an autoimmune disease, according to the National Institutes of Health, and the numbers are increasing. The rising prevalence of cancer and chronic diseases remain among the primary influences driving this surge. Camarus AB, Nanobiotix, NanoCarrier Co., Ltd., Selecta Biosciences, Starpharma Holdings Limited, Taiwan Liposome Co., Pfizer, Novartis, Merck & Co., and Bayer are some of the prominent players operating in the global Nanotechnology in Drug Delivery market. Several M&A’s along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-112060

Insights Presented in the Report “Amongst technology, nanoparticles segment holds the major share” Based on the technology type, the market is fragmented into nanoparticles, liposomes, nanocrystals, micelles, and others. The nanoparticles segment dominated the market with a share of 27.2% in 2019 and is expected to maintain its dominance during the forecast period owing to the better biocompatibility, non-immunogenicity, non-toxicity, and biodegradability compared to conventional approaches. “Amongst application, oncology is anticipated to dominate the market during the analyzed period” Further based on application, the market is mainly bifurcated into oncology, cardiovascular/physiology, anti-inflammatory/ immunology, neurology, anti-infective, and others. In 2019, oncology accounted for a maximum market revenue share of 36% and is expected to remain dominant during the analyzed period owing to the increasing development of nano-drug delivery in the oncology due to the advantages of nanoparticle (NP)-based drug delivery systems in cancer treatment, such as good pharmacokinetics, precise targeting of tumor cells, reduction of side effects, and drug resistance. However, the anti-inflammatory/ immunology segment is anticipated to grow at the highest CAGR over the forecast period. “North America signifies one of the largest markets of Nanotechnology in Drug Delivery Market” For a better understanding of the market dynamics of the Nanotechnology in Drug Delivery market, a detailed analysis was conducted for different regions across the globe including North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, Australia, South Korea, India, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of US$ 18.9 billion in 2019 owing to the increasing prevalence rate of cancer, presence of high disposable income, and rise in funding for R&D activities associated with Nanotechnology in Drug Delivery. For instance, Cancer is the leading cause of death in Canada and the second-leading cause, after heart disease, in the USA. Nearly 1.9 million new cancer cases and 693,000 cancer deaths were estimated in North America in 2018. Reasons to buy this report: • The study includes market sizing and forecasting analysis validated by authenticated key industry experts • The report presents a quick review of overall industry performance at one glance • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry • The study comprehensively covers the market across different segments • Deep dive regional level analysis of the industry Customization Options: The Nanotechnology in Drug Delivery Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count Email: [email protected] Tel: + 81 3 45720790

0 notes